| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 |
| 29 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Protara Therapeutics, Inc. (the “Company”) announced that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities, effective as of June 26, 2026. Dr. Nicacio's duties w... |
| 15 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders (the “Annual Meeting”) of Protara Therapeutics, Inc. (the “Company”) was held on June 12, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 55,060,500 shares of the Company’... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 |
| 30 Mar 2026 |
8-K: Regulation FD Disclosure
On March 30, 2026, Protara Therapeutics, Inc. (the “Company” or “Protara”) announced that the Company has received confirmation on the six-month complete response (“CR”) rate of the 25th Bacillus Calmette-Guérin (“BCG”)-Unresponsive pati... |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients |
| 24 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward Looking Statements 1 ©2026 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within th... |
| 15 Dec 2025 |
8-K: Other Events
We are issuing this opinion letter in our capacity as special U.S. counsel to Protara Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the issuance and sale of an aggregate of 1,956,521 shares (the “Shares”)... |
| 08 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
1. Introductory. Protara Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Unde... |
| 03 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients |
| 19 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
STARBORN - 1 Clinical Trial Interim Update November 19, 2025 |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders (the “Annual Meeting”) of Protara Therapeutics, Inc. (the “Company”) was held on June 11, 2025. As of April 16, 2025, the record date for the Annual Meeting, there were 38,579,021 shares of the Company’... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC |
| 28 Apr 2025 |
8-K: Regulation FD Disclosure; Other Events
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC |
| 05 Mar 2025 |
8-K: Results of Operations and Financial Condition
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025 |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure; Other Events
FORWARD LOOKING STATEMENTS 2 © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within t... |
| 11 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
1. Introductory. Protara Therapeutics, Inc a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Under... |
Loading...